Company profile
United Therapeutics Corporation
NASDAQ: UTHR · Healthcare · Biotechnology
#82 of 1,418 Healthcare companies by revenue56th-percentile growth
EA Score
92AFH 94DQ 98GM 72SS 90
v0.1 · 65/100 weight · provisional
↑ operating margin, disclosure history · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$3.2B
Rev growth YoY (TTM)
+5.9%
Net income (FY)
$1.3B
Employees
1,400
as of 2026-08-05
Market cap
$22.0B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.2B$3.2B2025
Net income$1.3B$1.3B2025
Operating income$1.5B$1.5B2025
Total assets$7.9B$7.9B2025
Liabilities$783.8M$783.8M2025
Equity$7.1B$7.1B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Tyvaso59%
Remodulin17%
Orenitram16%
Unituxin7%
Adcirca1%
Product and Service, Other1%
By geography
UNITED STATES95%
Non-US5%
The read
What is United Therapeutics Corporation’s revenue?
United Therapeutics Corporation booked $3.2B in FY2025 revenue, growing 11% year over year — about the middle of the pack among Healthcare companies we track, at a 41.9% net margin.
Peers · Healthcare
AdaptHealth Corp.67BBioMarin Pharmaceutical Inc.85ABrookdale Senior Living Inc.73BAstrana Health, Inc.75B+Waters Corporation82B+MiniMed Group, Inc. Common Stock73BNeighbors
Montgomery →Key facts
CEOMartine A. Rothblatt
SectorHealthcare
IndustryBiotechnology
HeadquartersSilver Spring, MD
ExchangeNASDAQ: UTHR
Employees1,400
IPO date1999-06-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.